HOUSTON–(COMMERCIAL THREAD)–InGeneron, Inc., a clinical-stage biotechnology company, announced the publication of a newly released study, titled “The composition of adipose-derived regenerative cells isolated from lipoaspirate using a novel point of care system does not depend on individual subject age, gender, body mass index, and ethnicity”published in the magazine Cells on December 21, 2022. The study, which characterized the composition of regenerative cells isolated from adipose tissue from 232 subjects using InGeneron’s Transpose® RT system, is the largest study of its kind to date.
Using high-fidelity technology to analyze the final cell product isolated from 232 subjects, the authors concluded that the composition, concentration and viability of regenerative cells were not significantly different between the groups of subjects studied. Additionally, the authors analyzed 37 of the regenerative cell samples using flow cytometry to characterize specific cell types and have yet to find significant differences between subject groups; gender was not addressed in this sub-analysis.
Dr. Christoph Schmitz, Head of Department of Anatomy II at Ludwig-Maximilians-University (Munich, Germany), InGeneron Medical Advisory Director and lead author of the article, explains: “It was reasonable for cell therapy critics to suspect that the quantity or quality of regenerative cells isolated from a 70-year-old patient might be lower than those isolated from a 30-year-old patient, resulting in different clinical outcomes between the two patients.However, our study indicates that no The carefully characterized regenerative cell samples in this study support the conclusion that age, gender, body mass index, and ethnicity produce similar regenerative cell products on average across all subject groups.
“While clinical outcomes often vary based on patient characteristics such as age,” adds Dr. Schmitz, “These findings should reduce concern that patients undergoing autologous regenerative cell therapy may experience different clinical outcomes due to differences in cell composition isolated from that patient, which is a groundbreaking discovery for the field.
Regarding the concentrations of various regenerative cell types within the final cell product, the study found InGeneron’s Transpose® RT system for isolating the highest concentration of cells known to be important for tissue regeneration compared to similar experimental methods and commercially available systems described in the scientific literature. Although the largest amount of viable cells isolated using InGeneron’s system has been published previously, Dr. Christopher Alt, director of medical and scientific affairs at InGeneron and co-author of the new study, says, “We believe this demonstrates the advantage our technology has in isolating the relevant types of regenerative cells, positioning InGeneron’s system as a leader among comparable.
In addition to stem and progenitor cells, the authors highlight the presence of M2 macrophages, which promote healing by reducing inflammation. The concentration of M2 macrophages isolated using InGeneron’s technology is, on average, three times higher than any other system.
The results of this study underscore important benefits of InGeneron’s technology, which is currently being evaluated in three FDA-approved clinical trials that are actively enrolling evidence for the treatment of partial thickness rotator cuff tears, osteoarthritis of the wrist and facet joint syndrome.
Citation: Schmitz C, Alt C, Azares AR, Pearce DA, Facile TR, Furia JP, Maffulli N, Huang C, Alt EU. The composition of adipose-derived regenerative cells isolated from lipoaspirate using a point of care system is not dependent on the individual age, gender, body mass index, and ethnicity of the subject. Cells 2023; 12(1):30.
Transposition information® RT system and ongoing clinical studies
InGeneron’s Transpose® The RT Cell Therapy Platform consists of a processing unit, a set of disposables, and Matrase®, a proprietary enzyme blend. The platform enables the isolation of regenerative cells from patient adipose tissue at the point of care for same-day treatment. The cells are administered back into the patient’s damaged tissue by injection under ultrasound or fluoroscopic guidance.
The transposition® RT System is being studied in several FDA-approved clinical trials and is currently available in the United States for research use only. Learn more about InGeneron’s active enrollment clinical studies at www.clinicaltrials.gov under the identifiers NCT03752827, NCT03513731And NCT03503305.
InGeneron is a clinical-stage biotechnology company developing innovative, safe, and evidence-based cell therapies. We are setting new standards of care by enabling minimally invasive treatments that unlock the healing potential of each patient’s regenerative cells processed at the point of care for same-day treatment. We are currently focused on helping patients affected by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to the development of clinically proven and FDA-approved therapies.